Aseem Malhotra
Aseem Malhotra is a medical researcher working in the fields of cardiovascular health and clinical nutrition. His published research examines coronary artery disease interventions, including the clinical roles of coronary stents, statin therapy, and target cholesterol levels. He has also published work evaluating dietary strategies for type 2 diabetes remission and the relationship between lifestyle factors, inflammation, and cardiovascular disease.
13 claims checked on air: 1 context 3 contradicted 1 overstated 8 supported
What they said on air
3 citing their own research
The World Health Organization officially declared obesity a global epidemic in 2004.
"So 2004, WHO announced it as an epidemic." (said at 0:42:30)
The World Health Organization (WHO) officially recognized and declared obesity as a global epidemic in June 1997 during the WHO Consultation on Obesity in Geneva, rather than in 2004. The conclusions and recommendations of this landmark meeting were published in the WHO Technical Report Series under the title "Obesity: preventing and managing the global epidemic" (PMID 11234459). While the World Health Assembly adopted the Global Strategy on Diet, Physical Activity and Health in 2004, the formal declaration of the obesity epidemic itself occurred seven years earlier.
Observational cohort studies and randomized controlled trials do not show a clear association between saturated fat consumption and heart disease.
"what I looked at the data, and it was very clear there was no clear association with saturated fat consumption and heart disease. [...] Both observational data and randomized control trials, no benefit like in lowering it, no association, nothing." (said at 0:44:21)
The statement is accurate regarding prospective observational cohort studies and certain mortality outcomes in randomized controlled trials (RCTs), but requires qualification. Meta-analyses of prospective cohort studies find no clear independent association between total dietary saturated fat intake and all-cause mortality, cardiovascular mortality, total coronary heart disease (CHD), or stroke. Similarly, long-term RCTs show no significant reduction in overall or cardiovascular mortality when reducing saturated fat. However, a Cochrane systematic review and meta-analysis of long-term RCTs established that reducing dietary saturated fat intake produces a statistically significant 17% reduction in combined cardiovascular events, particularly when saturated fats are replaced by polyunsaturated fats.
- supports: Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, car… (BMJ (Clinical research ed.) 2015) · cited 1441x in the literature
"Saturated fat intake was not associated with all cause mortality (relative risk 0.99, 95% confidence interval 0.91 to 1.09), CVD mortality (0.97, 0.84 to 1.12), total CHD (1.06, 0.95 to 1.17), ischemic stroke (1.02, 0.90 to 1.15), or type 2 diabetes (0.95, 0.88 to 1.03)." (abstract, results, passage verified)
pubmedfull study (doi) - partial: Reduction in saturated fat intake for cardiovascular disease. (The Cochrane database of systematic reviews 2020)
"The included long-term trials suggested that reducing dietary saturated fat reduced the risk of combined cardiovascular events by 17% (risk ratio (RR) 0.83; 95% confidence interval (CI) 0.70 to 0.98, 12 trials, 53,758 participants of whom 8% had a cardiovascular event, I² = 67%, GRADE moderate-quality evidence)." (abstract, results, passage verified)
pubmedfull study (doi)
Saturated fat consumption raises LDL cholesterol.
"and we know saturated fat raises LDL cholesterol" (said at 0:44:24)
Extensive randomized controlled trial evidence and systematic reviews consistently show that consumption of saturated fatty acids increases circulating LDL cholesterol (and conversely, reducing dietary saturated fat or replacing it with unsaturated fats lowers total and LDL cholesterol).
- supports: Reduction in saturated fat intake for cardiovascular disease. (The Cochrane database of systematic reviews 2020)
"There was little or no effect on cancer mortality, cancer diagnoses, diabetes diagnosis, HDL cholesterol, serum triglycerides or blood pressure, and small reductions in weight, serum total cholesterol, LDL cholesterol and BMI." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Impact of Replacement of Individual Dietary SFAs on Circulating Lipids and Other Biomarker… (Advances in nutrition (Bethesda, Md.) 2022) · cited 38x in the literature
"We observed reductions in LDL-cholesterol concentrations after the replacement of palmitic acid (16:0) with UFAs (-0.36 mmol/L; 95% CI: -0.50, -0.21 mmol/L; I2 = 96.0%, n = 18 RCTs) or oleic acid (18:1n-9) (-0.16 mmol/L; 95% CI: -0.28, -0.03 mmol/L; I2 = 89.6%, n = 9 RCTs), with a similar impact on total cholesterol and apoB concentrations." (abstract, results, passage verified)
pubmedfull study (doi)
Statins exhibit distinct anti-inflammatory and anti-clotting mechanisms independent of cholesterol lowering.
"statins had a separate effect to lower cholesterol, which is their anti-inflammatory and their anti-clotting." (said at 0:44:33)
The claim is supported. Extensive clinical and mechanistic literature confirms that HMG-CoA reductase inhibitors (statins) exert well-established 'pleiotropic' effects independent of their primary low-density lipoprotein (LDL) cholesterol-lowering pathway. By inhibiting the mevalonate pathway and the isoprenylation of small GTP-binding proteins (such as Rho, Ras, and Rac), statins mediate distinct anti-inflammatory effects (e.g., reductions in hs-CRP, proinflammatory cytokines, and leukocyte adhesion) and antithrombotic/anti-clotting effects (e.g., attenuation of tissue factor expression, inhibition of platelet activation and thrombus formation, and modulation of fibrin clot properties).
The Framingham Heart Study began longitudinal data collection in Massachusetts in 1948.
"So these are the Framingham studies that, uh, you know, started in Massachusetts in 1948 and went over decades looking at thousands of people" (said at 0:46:54)
The statement is accurate. The Framingham Heart Study is the longest-running cardiovascular epidemiological cohort study; it was established in 1948 in Framingham, Massachusetts, collecting longitudinal data over multiple generations across several decades.
In the Framingham Heart Study data summarized by William Castelli in 1996, LDL cholesterol was useless as a predictor of coronary artery disease unless LDL was above ~7.8 mmol/L (~250 mg/dL).
"William Castelli is a cardiologist, and he published—uh, he was a co-director of Framingham, and in 1996 he published in one of the cardiology, major cardiology journals, a summary of Framingham specifically looking at LDL cholesterol. ... And he said from Framingham, unless your LDL was above 7.8, 8 millimoles, which by the way, I think in your units is probably 250 or 300, 250 probably. ... It absolutely had no—it was useless as a predictor for coronary artery disease." (said at 0:47:11)
In his 1996 review summarizing Framingham Heart Study insights on lipid risk factors, William Castelli did not state that LDL cholesterol was useless as a predictor of coronary artery disease below ~7.8 mmol/L (~300 mg/dL). Rather, Castelli identified abnormal lipids (including atherogenic low-density lipoproteins) as one of the three primary cardiovascular risk factors, while noting that because most coronary heart disease events occur in individuals with average total cholesterol levels (overlap between cases and non-cases), assessing isolated total cholesterol or LDL without HDL is insufficient. He advocated for using the total cholesterol-to-HDL cholesterol ratio and triglyceride levels to more effectively identify patients at high risk who require treatment.
- contradicts: Lipids, risk factors and ischaemic heart disease. (Atherosclerosis 1996) · cited 327x in the literature
"Among these, the three most important are (1) abnormal lipids, including the fact that there are more than 15 types of cholesterol-containing lipoproteins and four different types of triglyceride-rich particles, some of which are very atherogenic, (2) high blood pressure, and (3) cigarette smoking... Firstly, the ratio of total cholesterol to high density cholesterol (HDL cholesterol) should be determined, followed by measurement of plasma triglyceride concentrations. This will allow differentiation of whether the low density lipoproteins (LDL), HDL cholesterol or triglyceride-rich particles such as the small dense beta-very low density lipoproteins (VLDL) are the major cause for concern." (abstract, results, passage verified)
pubmedfull study (doi)
When corrected for triglyceride and HDL levels, LDL cholesterol loses statistical significance as a predictor of heart disease.
"When you correct for triglycerides and HDL, okay, which by the way is a more important predictor of heart disease, LDL loses its significance completely." (said at 0:48:10)
Large-scale prospective cohort studies and individual-participant meta-analyses demonstrate that LDL cholesterol (LDL-C) and atherogenic apoB-containing particles remain statistically significant, independent predictors of coronary heart disease (CHD) after multivariable adjustment for HDL cholesterol and triglycerides. In the Emerging Risk Factors Collaboration analysis of 302,430 individuals across 68 prospective studies, directly measured LDL-C remained significantly associated with CHD risk even after adjustment for conventional risk factors including HDL-C and triglycerides (hazard ratio 1.38 per 1-SD increase, 95% CI 1.09–1.73). In fact, the inverse of the guest's claim occurred for triglycerides: after adjusting for HDL-C and non-HDL-C/LDL-C, triglycerides lost independent statistical significance for CHD (adjusted HR 0.99, 95% CI 0.94–1.05).
- contradicts: Major lipids, apolipoproteins, and risk of vascular disease. (JAMA 2009) · cited 2789x in the literature
"Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C... For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C." (abstract, results)
pubmedfull study (doi)
A systematic review of over 30 randomized controlled trials found no clear relationship between the degree of LDL reduction from cholesterol-lowering drugs and prevention of cardiovascular events.
"So myself and two cardiologists did a systematic review of the totality of drug industry-sponsored trials, by the way, and some diet trials, but many drug industry-sponsored trials, all of the randomized controlled trials on cholesterol-lowering drugs: statins, PCSK9, blah, blah. Was there a clear relationship as you lowered LDL in low-risk and high-risk patients, Mark, okay, over 30 studies, was there a relationship with lowering LDL and preventing cardiovascular events? No." (said at 0:48:30)
The speaker accurately describes the findings of a published systematic review of 35 randomized controlled trials (PMID 32747335), which he co-authored. The review analyzed trials evaluating LDL cholesterol targets across diverse risk populations and concluded that achieving specific LDL target levels through drug therapy did not confer consistent cardiovascular benefit, questioning the direct relationship between LDL-C lowering as a surrogate target and cardiovascular event reduction. A subsequent 2022 systematic review and meta-regression in JAMA Internal Medicine (PMID 35285850) evaluating statin trials similarly concluded that a conclusive relationship between the magnitude of absolute LDL-C reduction and individual clinical outcomes (all-cause mortality, myocardial infarction, stroke) was not established.
Approximately 1 in 100 (or up to 1 in 50) people prescribed statins develop type 2 diabetes as a result of the medication.
"What else do statins do? They cause insulin resistance. Say 1 in 100 people get type 2 diabetes because of statins. ... Some some studies say 1 in 50, right? Will get type 2 diabetes because of the statin." (said at 0:49:46)
The claim that 1 in 100 (or up to 1 in 50) people develop type 2 diabetes because of statins overstates the excess risk attributable to the medication. In large collaborative meta-analyses of randomized controlled trials, statin therapy was associated with a modest 9% relative increase in incident diabetes (odds ratio 1.09), corresponding to an absolute risk of 1 additional case of diabetes for every 255 patients treated over an average of 4 years (approximately 1 in 255, or ~0.4%). Even when comparing intensive-dose statin therapy to moderate-dose therapy, the number needed to harm per year was 498 (approximately 2.0 additional cases per 1,000 patient-years).
- contradicts: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin … (Lancet (London, England) 2010) · cited 2464x in the literature
"Statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials... Treatment of 255 (95% CI 150-852) patients with statins for 4 years resulted in one extra case of diabetes." (abstract, results)
pubmedfull study (doi) - contradicts: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: … (JAMA 2011) · cited 1395x in the literature
"In 5 statin trials with 32,752 participants without diabetes at baseline, 2749 developed diabetes (1449 assigned intensive-dose therapy, 1300 assigned moderate-dose therapy, representing 2.0 additional cases in the intensive-dose group per 1000 patient-years)... As compared with moderate-dose statin therapy, the number needed to harm per year for intensive-dose statin therapy was 498 for new-onset diabetes" (abstract, results, passage verified)
pubmedfull study (doi)
A 2016 systematic review of observational cohort studies in people over age 60 found an inverse association between LDL cholesterol and all-cause mortality.
"2016, and the reason we did this, me and a number of international scientists, we decided to do a systematic review of observational data looking at people over 60. ... but what was surprising was there was an inverse association with LDL cholesterol and all-cause mortality. In other words, statistically, if you're over 60, the higher LDL, the less likely you are to die." (said at 0:54:26)
A 2016 systematic review by Ravnskov et al. (published in BMJ Open) evaluated 19 cohort studies comprising 30 cohorts and 68,094 participants aged 60 years and older. The authors reported an inverse association between LDL cholesterol and all-cause mortality in 16 of the 28 cohorts where all-cause mortality was recorded (representing 92% of analyzed participants), with no association found in the remaining cohorts. Because the underlying evidence base consists of observational cohort studies susceptible to reverse causation (e.g., frailty, terminal illness, or malnutrition lowering cholesterol levels prior to death) and residual confounding, the certainty of evidence for this observational association is low.
In the Framingham Heart Study, after age 50, mortality increased as total cholesterol dropped.
"another thing that was interesting from Framingham which wasn't well publicized is that when after people hit 50 years old, as their cholesterol dropped, their mortality increased." (said at 0:54:40)
Published analyses of the Framingham Heart Study support the statement. In a 30-year follow-up analysis of Framingham participants published in JAMA (1987), researchers reported that for individuals over age 50, falling total cholesterol levels over a 14-year period were associated with an 11% increase in overall mortality and a 14% increase in cardiovascular mortality for every 1 mg/dL per year decrease in cholesterol. A subsequent 1993 analysis confirmed that total cholesterol was negatively associated with all-cause mortality at age 80 and non-significantly or negatively associated in middle-to-older age groups. The original study authors noted that this observational association in older adults is confounded by reverse causality, wherein developing chronic illnesses cause cholesterol levels to drop prior to death.
A 2016 systematic review of observational cohort studies found no association between LDL cholesterol levels and cardiovascular disease in individuals aged 60 and older.
"So we looked at: was there first of all any association if you're over 60 with LDL cholesterol and heart disease? We found none." (said at 0:55:08)
A 2016 systematic review by Ravnskov and colleagues evaluated 19 cohort studies (30 cohorts, 68,094 individuals aged 60 and older) examining LDL cholesterol and mortality outcomes. Regarding cardiovascular mortality across 9 cohorts where it was assessed, seven cohorts found no association with LDL-C levels, and two cohorts found cardiovascular mortality was highest in the lowest LDL-C quartile. For all-cause mortality, an inverse association or lack of association was observed. Because this evidence is derived entirely from observational cohort studies prone to reverse causation and residual confounding, the certainty of evidence is low.
Low cholesterol levels are associated with an increased incidence of cancer.
"And we also know there is an association—I'll use this word, an association, right? Not definitely causal—between low cholesterol and cancer." (said at 0:55:50)
Epidemiological cohort studies have repeatedly demonstrated an observational association between low serum total cholesterol levels and an increased incidence or mortality of cancer. However, extensive research—including randomized intervention trials, long-term prospective cohorts, and Mendelian randomization analyses—indicates that this relationship is non-causal. Instead, the inverse association is largely explained by reverse causality (subclinical, undiagnosed malignancies consuming or suppressing serum lipids prior to diagnosis) and confounding factors such as underlying liver dysfunction or low albumin levels. Because the speaker explicitly qualified the statement as an observational association rather than a causal link, the statement accurately reflects the epidemiological evidence.
- supports: Low serum cholesterol, cancer and other noncardiovascular disorders. (Atherosclerosis 1992) · cited 30x in the literature
"A review of the evidence from ecological, cross-cultural comparisons, prospective epidemiological cohort studies and intervention trials provides no indication for a cause-and-effect association between low serum cholesterol or serum cholesterol lowering and the risk of cancer, except possibly at very low levels." (abstract, passage verified)
pubmedfull study (doi) - supports: Liver diseases and low serum albumin as potential confounders in the association between l… (Journal of clinical lipidology 2026)
"While cholesterol-lowering trials have consistently demonstrated cardiovascular disease (CVD) benefits, some observational studies showed an elevated mortality risk from all-cause, CVD, and cancer in those with low total cholesterol (TC)." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Review of the epidemiological evidence for a possible relationship between hypocholesterol… (Cancer research 1983) · cited 57x in the literature
"the available data do not substantiate any direct cause and effect relationship between low blood cholesterol levels and cancer. Rather, the data suggest that low cholesterol levels may serve as a "marker," possibly genetic, and in only small numbers of male individuals in any given population" (abstract, conclusions, passage verified)
pubmed
Fact-checked episodes
Publications